News & events

17 May 2013Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS
08 May 2013Actelion provides update on Phase III GRIPHON study with selexipag in pulmonary arterial hypertension - Study continues
18 Apr 2013Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
16 Apr 2013Actelion delivers strong first quarter 2013 results
14 Mar 2013Actelion nominates Mr. John J. Greisch for election to the Board of Directors
18 Feb 2013Actelion obtains marketing approval for Epoprostenol "ACT" in Japan
14 Feb 2013Actelion delivers strong performance in 2012 - Getting ready for Opsumit launch in 2013
07 Jan 2013Actelion to present at the 31st Annual J.P. Morgan Healthcare Conference - Delivering on our strategy
21 Dec 2012Actelion's novel antibiotic cadazolid to move into Phase III clinical development in patients suffering from Clostridium difficile associated diarrhea
18 Dec 2012Actelion's ponesimod successful in mid-stage trial in patients with moderate to severe chronic plaque psoriasis - Ponesimod to proceed to Phase III clinical development in psoriasis
14 Dec 2012Actelion announces acceptance of the New Drug Application for macitentan by the US Food and Drug Administration
22 Nov 2012Actelion submits the registration dossier for macitentan (Opsumit) to the European Medicines Agency (EMA)
23 Oct 2012Phase III PAH outcome study with macitentan (Opsumit) presented at CHEST - Significant reduction in the risk of morbidity and mortality
22 Oct 2012Actelion submits a New Drug Application to the FDA for macitentan (Opsumit) for the treatment of patients with pulmonary arterial hypertension
18 Oct 2012Actelion announces nine months 2012 financial results
11 Sep 2012Actelion implements cost saving initiative
10 Sep 2012Macitentan Phase III PAH outcome study results to be presented at CHEST 2012
19 Jul 2012Actelion announces Half Year 2012 financial results
12 Jul 2012Actelion announces cost saving initiative to be implemented by the end of 2012
08 May 2012Actelion presents its strategy for value creation
Page:  1 2 3 4 5 6 7 8 9 10 11 12 13 14

Corporate events

18 July 2013

HY Results 2013
17 Oct 2013

Q3 Results 2013
13 Feb 2014

FY Results 2013
08 May 2014

AGM 2014
Learn more
 

Top of pageSendbookmarkPrint page